Conventional CNS assets (seltorexant, esketamine) post cleaner Phase 3 functional-blinding profiles than classic psychedelics this quarter.

Predicted 2026-08-29 · Resolves 2026-11-30 · clinical · USA

58%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

One of the biggest problems with testing psychedelics in clinical trials is that people can usually tell whether they took the real drug or a dummy pill — which can skew results. Drugs like seltorexant and esketamine (already-approved treatments) don't cause obvious hallucinations, so trial participants are less likely to guess which group they're in. The prediction is that by November 30, 2026, an established drug will post clean, significant results while no psychedelic trial manages the same.

Resolution rule: YES if, by 2026-11-30, at least one seltorexant or esketamine Phase 3 readout is published with a statistically significant primary endpoint AND no classic-psychedelic Phase 3 readout in the same window achieves a significant primary endpoint free of a formally raised functional-unblinding concern. Source: sponsor press releases, clinicaltrials.gov, peer-reviewed/preprint publications. Check date: 2026-11-30.

Orexin and NMDA mechanisms are better characterized with more tractable blinding; classic psychedelic trials continue to face functional-unblinding critiques. Restricting to a documentable blinding/quality comparison keeps it falsifiable.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →